SCHEMBL19901008

SCHEMBL19901008

O=C(OOC(F)(F)F)c1ccc2ncsc2c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.57
RAB9A P51151 9/20 0.57
TDP1 Q9NUW8 3/20 0.57
KDM4E B2RXH2 2/20 0.57
HKDC1 Q2TB90 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
NTRK1 P04629 3/20 0.55
NTRK2 Q16620 3/20 0.55
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
POLB P06746 1/20 0.52
ALDH1A1 P00352 1/20 0.48
PKM P14618 1/20 0.47
GFER P55789 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19901007 0.86 NPC1 (0.60) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL19900857 0.81 NPC1 (0.62) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL28327199 0.81 NPC1 (0.66) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL507242 0.78 RAB9A (0.66) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL18062419 0.78 NPC1 (0.66) NPC1RAB9ATDP1KDM4EHKDC1
Trifluoroacetic Acid SCHEMBL5025946 0.75 NPC1 (0.82) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL11988932 0.75 NPC1 (0.66) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL2665689 0.74 TDP1 (0.63) NPC1RAB9ATDP1KDM4EHKDC1
SCHEMBL192332 0.74 NPC1 (1.00) NPC1RAB9ATDP1KDM4EHKDC1
Hydrochloric Acid SCHEMBL4255724 0.72 NPC1 (0.96) NPC1RAB9ATDP1KDM4EHKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504205-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS Ardelyx, Inc. (US) 2019-07-03 EP disclosed
WO-2018039386-A1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS ARDELYX, INC. (US) 2018-03-01 WO disclosed